Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
9
WINT Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
-11.7%
Day range:
$0.0097 - $0.0114
52-week range:
$0.0078 - $4.2900
Dividend yield:
0%
P/E ratio:
0.00x
P/S ratio:
0.26x
P/B ratio:
0.41x
Volume:
129.6K
Avg. volume:
385.7K
1-year change:
-99.69%
Market cap:
$357.3K
Revenue:
--
EPS (TTM):
-$8.51
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WINT
Windtree Therapeutics, Inc.
|
-- | -$39.00 | -- | -94.17% | $4.0000 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
CRIS
Curis, Inc.
|
$3.2M | -$0.43 | -2.86% | -65.51% | $14.00 |
|
ENZN
Enzon Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- |
|
LADX
LadRx Corp.
|
-- | -- | -- | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WINT
Windtree Therapeutics, Inc.
|
$0.0106 | $4.0000 | $357.3K | 0.00x | $0.00 | 0% | 0.26x |
|
AGEN
Agenus, Inc.
|
$3.36 | $12.33 | $121.4M | -- | $0.00 | 0% | 0.85x |
|
CRIS
Curis, Inc.
|
$1.11 | $14.00 | $14.4M | -- | $0.00 | 0% | 1.06x |
|
ENZN
Enzon Pharmaceuticals, Inc.
|
$0.06 | -- | $4.5M | 96.91x | $0.00 | 0% | 225.50x |
|
LADX
LadRx Corp.
|
$0.1100 | -- | $54.5K | 0.84x | $0.00 | 0% | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$0.32 | $5.50 | $44.6M | -- | $0.00 | 0% | 5.20x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WINT
Windtree Therapeutics, Inc.
|
974.23% | 2.926 | 568.87% | 0.01x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.019 | 285.06% | 0.03x |
|
CRIS
Curis, Inc.
|
192.35% | 2.868 | 144.76% | 0.62x |
|
ENZN
Enzon Pharmaceuticals, Inc.
|
-- | 2.463 | -- | 80.10x |
|
LADX
LadRx Corp.
|
-- | 2.863 | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WINT
Windtree Therapeutics, Inc.
|
-$360K | -$3.8M | -320.18% | -760.4% | -- | -$6.4M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
CRIS
Curis, Inc.
|
$3.1M | -$6.9M | -147.67% | -461.34% | -218.01% | -$5.6M |
|
ENZN
Enzon Pharmaceuticals, Inc.
|
-- | -$229K | -5.37% | -5.37% | -1250% | -$1M |
|
LADX
LadRx Corp.
|
-- | -$719.8K | -- | -- | -- | -$552.8K |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
Windtree Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns WINT or AGEN?
Agenus, Inc. has a net margin of -- compared to Windtree Therapeutics, Inc.'s net margin of -116.82%. Windtree Therapeutics, Inc.'s return on equity of -760.4% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital WINTWindtree Therapeutics, Inc.-- -$1.08 $1.3M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About WINT or AGEN?
Windtree Therapeutics, Inc. has a consensus price target of $4.0000, signalling upside risk potential of 37635.85%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 267.06%. Given that Windtree Therapeutics, Inc. has higher upside potential than Agenus, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than Agenus, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WINTWindtree Therapeutics, Inc.0 0 0 AGENAgenus, Inc.2 1 0 -
Is WINT or AGEN More Risky?
Windtree Therapeutics, Inc. has a beta of 0.663, which suggesting that the stock is 33.733% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.
-
Which is a Better Dividend Stock WINT or AGEN?
Windtree Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics, Inc. pays 36.77% of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WINT or AGEN?
Windtree Therapeutics, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Windtree Therapeutics, Inc.'s net income of -$28.1M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Windtree Therapeutics, Inc.'s price-to-earnings ratio is 0.00x while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics, Inc. is 0.26x versus 0.85x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WINTWindtree Therapeutics, Inc.0.26x 0.00x -- -$28.1M AGENAgenus, Inc.0.85x -- $30.2M $63.9M
-
Which has Higher Returns WINT or CRIS?
Curis, Inc. has a net margin of -- compared to Windtree Therapeutics, Inc.'s net margin of -243.36%. Windtree Therapeutics, Inc.'s return on equity of -760.4% beat Curis, Inc.'s return on equity of -461.34%.
Company Gross Margin Earnings Per Share Invested Capital WINTWindtree Therapeutics, Inc.-- -$1.08 $1.3M CRISCuris, Inc.98.52% -$0.49 $15.9M -
What do Analysts Say About WINT or CRIS?
Windtree Therapeutics, Inc. has a consensus price target of $4.0000, signalling upside risk potential of 37635.85%. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1161.26%. Given that Windtree Therapeutics, Inc. has higher upside potential than Curis, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than Curis, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WINTWindtree Therapeutics, Inc.0 0 0 CRISCuris, Inc.4 0 0 -
Is WINT or CRIS More Risky?
Windtree Therapeutics, Inc. has a beta of 0.663, which suggesting that the stock is 33.733% less volatile than S&P 500. In comparison Curis, Inc. has a beta of 3.078, suggesting its more volatile than the S&P 500 by 207.818%.
-
Which is a Better Dividend Stock WINT or CRIS?
Windtree Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics, Inc. pays 36.77% of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WINT or CRIS?
Windtree Therapeutics, Inc. quarterly revenues are --, which are smaller than Curis, Inc. quarterly revenues of $3.2M. Windtree Therapeutics, Inc.'s net income of -$28.1M is lower than Curis, Inc.'s net income of -$7.7M. Notably, Windtree Therapeutics, Inc.'s price-to-earnings ratio is 0.00x while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics, Inc. is 0.26x versus 1.06x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WINTWindtree Therapeutics, Inc.0.26x 0.00x -- -$28.1M CRISCuris, Inc.1.06x -- $3.2M -$7.7M
-
Which has Higher Returns WINT or ENZN?
Enzon Pharmaceuticals, Inc. has a net margin of -- compared to Windtree Therapeutics, Inc.'s net margin of --. Windtree Therapeutics, Inc.'s return on equity of -760.4% beat Enzon Pharmaceuticals, Inc.'s return on equity of -5.37%.
Company Gross Margin Earnings Per Share Invested Capital WINTWindtree Therapeutics, Inc.-- -$1.08 $1.3M ENZNEnzon Pharmaceuticals, Inc.-- -$0.02 $43.2M -
What do Analysts Say About WINT or ENZN?
Windtree Therapeutics, Inc. has a consensus price target of $4.0000, signalling upside risk potential of 37635.85%. On the other hand Enzon Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Windtree Therapeutics, Inc. has higher upside potential than Enzon Pharmaceuticals, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than Enzon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WINTWindtree Therapeutics, Inc.0 0 0 ENZNEnzon Pharmaceuticals, Inc.0 0 0 -
Is WINT or ENZN More Risky?
Windtree Therapeutics, Inc. has a beta of 0.663, which suggesting that the stock is 33.733% less volatile than S&P 500. In comparison Enzon Pharmaceuticals, Inc. has a beta of 0.196, suggesting its less volatile than the S&P 500 by 80.447%.
-
Which is a Better Dividend Stock WINT or ENZN?
Windtree Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enzon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics, Inc. pays 36.77% of its earnings as a dividend. Enzon Pharmaceuticals, Inc. pays out -163.88% of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WINT or ENZN?
Windtree Therapeutics, Inc. quarterly revenues are --, which are smaller than Enzon Pharmaceuticals, Inc. quarterly revenues of --. Windtree Therapeutics, Inc.'s net income of -$28.1M is lower than Enzon Pharmaceuticals, Inc.'s net income of -$824K. Notably, Windtree Therapeutics, Inc.'s price-to-earnings ratio is 0.00x while Enzon Pharmaceuticals, Inc.'s PE ratio is 96.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics, Inc. is 0.26x versus 225.50x for Enzon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WINTWindtree Therapeutics, Inc.0.26x 0.00x -- -$28.1M ENZNEnzon Pharmaceuticals, Inc.225.50x 96.91x -- -$824K
-
Which has Higher Returns WINT or LADX?
LadRx Corp. has a net margin of -- compared to Windtree Therapeutics, Inc.'s net margin of --. Windtree Therapeutics, Inc.'s return on equity of -760.4% beat LadRx Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital WINTWindtree Therapeutics, Inc.-- -$1.08 $1.3M LADXLadRx Corp.-- -$1.45 -- -
What do Analysts Say About WINT or LADX?
Windtree Therapeutics, Inc. has a consensus price target of $4.0000, signalling upside risk potential of 37635.85%. On the other hand LadRx Corp. has an analysts' consensus of -- which suggests that it could grow by 408990.91%. Given that LadRx Corp. has higher upside potential than Windtree Therapeutics, Inc., analysts believe LadRx Corp. is more attractive than Windtree Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WINTWindtree Therapeutics, Inc.0 0 0 LADXLadRx Corp.0 0 0 -
Is WINT or LADX More Risky?
Windtree Therapeutics, Inc. has a beta of 0.663, which suggesting that the stock is 33.733% less volatile than S&P 500. In comparison LadRx Corp. has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.583%.
-
Which is a Better Dividend Stock WINT or LADX?
Windtree Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LadRx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics, Inc. pays 36.77% of its earnings as a dividend. LadRx Corp. pays out -- of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WINT or LADX?
Windtree Therapeutics, Inc. quarterly revenues are --, which are larger than LadRx Corp. quarterly revenues of --. Windtree Therapeutics, Inc.'s net income of -$28.1M is lower than LadRx Corp.'s net income of -$719.3K. Notably, Windtree Therapeutics, Inc.'s price-to-earnings ratio is 0.00x while LadRx Corp.'s PE ratio is 0.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics, Inc. is 0.26x versus -- for LadRx Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WINTWindtree Therapeutics, Inc.0.26x 0.00x -- -$28.1M LADXLadRx Corp.-- 0.84x -- -$719.3K
-
Which has Higher Returns WINT or PSTV?
Plus Therapeutics, Inc. has a net margin of -- compared to Windtree Therapeutics, Inc.'s net margin of -316.61%. Windtree Therapeutics, Inc.'s return on equity of -760.4% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital WINTWindtree Therapeutics, Inc.-- -$1.08 $1.3M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About WINT or PSTV?
Windtree Therapeutics, Inc. has a consensus price target of $4.0000, signalling upside risk potential of 37635.85%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1595.96%. Given that Windtree Therapeutics, Inc. has higher upside potential than Plus Therapeutics, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than Plus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WINTWindtree Therapeutics, Inc.0 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is WINT or PSTV More Risky?
Windtree Therapeutics, Inc. has a beta of 0.663, which suggesting that the stock is 33.733% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock WINT or PSTV?
Windtree Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics, Inc. pays 36.77% of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WINT or PSTV?
Windtree Therapeutics, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Windtree Therapeutics, Inc.'s net income of -$28.1M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Windtree Therapeutics, Inc.'s price-to-earnings ratio is 0.00x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics, Inc. is 0.26x versus 5.20x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WINTWindtree Therapeutics, Inc.0.26x 0.00x -- -$28.1M PSTVPlus Therapeutics, Inc.5.20x -- $1.4M -$4.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
